FindTrial
Sign In

The clinical research of intensive chemotherapy to triple negative breast cancer

The clinical research of intensive chemotherapy to triple negative breast cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOS-14005503
Enrollment
Unknown
Registered
2014-11-07
Start date
2014-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

triple negative breast cancer

Interventions

1:chemotherapy
2:observation

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. female patients; 2. age of patients: 18-70 years old; 3. unilateral breast cancer (including invasive ductal carcinoma and nvasive lobular carcinoma); 4. ER(-), PR(-), Her-2(-); 5. the last chemotherapy time: 1-2 year. Any prior chemotherapy regimens; 6. Patients with voluntary.

Exclusion criteria

Exclusion criteria: 1. patients can not complete 2 cycle chemotherapy regularly; 2. Severe injury of liver and kidney function; 3. progressive disease during the period of chemotherapy; 4. one of the three protien (ER, PR, HER-2) express positive; 5. Patients choose to stop or loss to follow-up.

Design outcomes

Primary

MeasureTime frame
local recurrence;distant metastasis;—

Countries

China

Contacts

Public ContactWang Xiaodong
wxd65@sohu.com+86 18980601579

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026